Rapport therapeutics announces new phase 1 data, further supporting rap-219's transformative potential for cns disorders

Rapport announced new data from its phase 1 pet and mad-2 trials for rap-219 being studied as a novel precision medicine for patients with cns disorders.

RAPP Ratings Summary

RAPP Quant Ranking